Back to User profile » Professor Afisi S Ismaila

Papers published by Professor Afisi S Ismaila:


Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial

Halpin DM, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, Risebrough NA, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2745-2755

Published Date: 25 October 2022

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting

Halpin DM, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, Tritton T, Massey O, Wild R, Snowise N, Nikitin K, Sharma R, Ismaila AS, Vogelmeier CF

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2417-2429

Published Date: 24 September 2022

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain

Neches García V, Vallejo-Aparicio LA, Ismaila AS, Sicras-Mainar A, Sicras-Navarro A, González C, Cuervo R, Shukla S, García-Peñuela M

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2161-2174

Published Date: 7 September 2022

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial

Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1633-1642

Published Date: 25 July 2022

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England

Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1455-1466

Published Date: 22 June 2022

Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation

Mannino D, Bogart M, Germain G, Huang SP, Ismaila AS, Laliberté F, Jung Y, MacKnight SD, Stiegler MA, Duh MS

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:491-504

Published Date: 5 March 2022

Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England

Sansbury LB, Lipson DA, Bains C, Anley GA, Rothnie KJ, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:415-426

Published Date: 3 March 2022

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3105-3118

Published Date: 13 November 2021

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England

Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2591-2604

Published Date: 15 September 2021

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective

Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, Izquierdo Alonso JL, Riesco Miranda JA, Soler-Cataluña JJ, Huerta A, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1621-1632

Published Date: 10 July 2020

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:439-460

Published Date: 26 February 2020

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial

Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DMG, Han MK, Lomas DA

International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2681-2695

Published Date: 29 November 2019

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease

Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2121-2129

Published Date: 12 September 2019

COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners

Meeraus W, Wood R, Jakubanis R, Holbrook T, Bizouard G, Despres J, Correia Da Silva C, Nachbaur G, Landis SH, Punekar Y, Aguilaniu B, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:51-63

Published Date: 18 December 2018

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis

Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1863-1881

Published Date: 9 September 2015